RPRX — Royalty Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $26.74bn
- $37.44bn
- $2.38bn
Annual cashflow statement for Royalty Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | -213 | -113 | 38.4 | 57.9 | -415 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 2,018 | 2,144 | 2,988 | 2,769 | 2,490 |
| Capital Expenditures | -2,192 | -1,742 | -2,116 | -2,506 | -1,698 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 321 | 712 | 42.7 | -172 | 83.5 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1,870 | -1,029 | -2,073 | -2,678 | -1,614 |
| Financing Cash Flow Items | -602 | -612 | -486 | -504 | -535 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 385 | -945 | -2,149 | 361 | -1,186 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 532 | 170 | -1,234 | 452 | -310 |